Treatment with metformin is associated with a prolonged survival in patients with hepatocellular carcinoma.
Lena SchulteBernhard ScheinerTorsten VoigtländerSandra KochNora SchweitzerSilke MarhenkePhilipp IvanyiMichael P MannsThomas RodtJan B HinrichsArndt WeinmannMatthias PinterArndt VogelMartha M KirsteinPublished in: Liver international : official journal of the International Association for the Study of the Liver (2019)
Treatment with metformin was associated with an improved survival in patients with T2DM and HCC. This effect was most pronounced in patients at potentially curative tumour stages.